Skip to main content

Advertisement

Log in

Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the effects of vitreomacular adhesion (VMA) on intravitreal ranibizumab treatment in Japanese patients with exudative age-related macular degeneration (AMD).

Methods

This was a retrospective comparative study that included 123 eyes from 123 patients with exudative AMD. The presence or absence of VMA was examined by spectral domain optical coherence tomography. The association of VMA with best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at 3, 6, and 12 months after ranibizumab treatment was evaluated.

Results

In the group of eyes without VMA [VMA(−)], the mean BCVA was 0.41 logMAR at baseline and significantly improved to 0.28, 0.30, and 0.29 logMAR at 3, 6, and 12 months following the initiation of treatment (P < 0.0001, <0.0001, <0.0001), respectively. In the group of eyes with VMA [VMA(+)], the mean BCVA was 0.42 logMAR at baseline, and there was no improvement at any of the measurement time-points during the follow-up period [0.39, 0.40, and 0.39 logMAR at 3, 6, and 12 months (P = 0.53, 0.75, 0.67), respectively]. The mean baseline CRT in the VMA(−) and VMA(+) groups was 326 and 370 µm, respectively, decreasing to 195 and 293 µm (P < 0.0001 and P = 0.0070), respectively, at 12 months. A better baseline BCVA was associated with poor visual response to intravitreal ranibizumab.

Conclusions

Our study of Japanese patients with AMD managed in real-world clinical practice revealed that both VMA and BCVA at baseline were associated with a poor visual response to intravitreal ranibizumab. These results are in agreement with previously reported findings for other ethnic groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Weber-Krause B, Eckardt U. Incidence of posterior vitreous detachment in eyes with and without age-related macular degeneration: an ultrasonic study [in German]. Ophthalmologe. 1996;93:660–5.

    Article  PubMed  CAS  Google Scholar 

  2. Ondes F, Yilmaz G, Acar MA, Unlu N, Kocaoglan H, Arsan AK. Role of the vitreous in age-related macular degeneration. Jpn J Ophthalmol. 2000;44:91–3.

    Article  PubMed  CAS  Google Scholar 

  3. Quaranta-El Maftouhi M, Mauget-Faysse M. Anomalous vitreoretinal adhesions in patients with exudative age-related macular degeneration: an OCT study. Eur J Ophthalmol. 2006;16:134–7.

    PubMed  CAS  Google Scholar 

  4. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144:741–6.

    Article  PubMed  Google Scholar 

  5. Robison CD, Krebs I, Binder S, Barbazetto IA, Kotsolis AI, Yannuzzi LA, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol. 2009;148(79–82):e72.

    Google Scholar 

  6. Nomura Y, Ueta T, Iriyama A, Inoue Y, Obata R, Tamaki Y, et al. Vitreomacular interface in typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Ophthalmology. 2011;118:853–9.

    Article  PubMed  Google Scholar 

  7. Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146:218–27.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology. 2011;118:101–10.

    Article  PubMed  Google Scholar 

  9. Cho HJ, Baek JS, Lee DW, Cho SW, Kim CG, Kim JW. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Retina. 2013;33:2126–32.

    Article  PubMed  CAS  Google Scholar 

  10. Mayr-Sponer U, Waldstein SM, Kundi M, Ritter M, Golbaz I, Heiling U, et al. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology. 2013;120:2620–9.

    Article  PubMed  Google Scholar 

  11. Uney GO, Unlu N, Acar MA, Hazirolan D, Altiparmak UE, Yalniz-Akkaya Z, et al. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration. Retina. 2014;34:32–7.

    Article  PubMed  CAS  Google Scholar 

  12. Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392–6.

    Article  PubMed  Google Scholar 

  13. Obata R, Yanagi Y, Kami J, Takahashi H, Inoue Y, Tamaki Y. Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration. Jpn J Ophthalmol. 2006;50:354–60.

    Article  PubMed  Google Scholar 

  14. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.

    Article  PubMed  Google Scholar 

  15. Iranmanesh R, Eandi CM, Peiretti E, Klais CM, Garuti S, Goldberg DE, et al. The nature and frequency of neovascular age-related macular degeneration. Eur J Ophthalmol. 2007;17:75–83.

    PubMed  CAS  Google Scholar 

  16. Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120:2611–9.

    Article  PubMed  Google Scholar 

  17. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.

    Article  PubMed  CAS  Google Scholar 

  18. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.

    Article  PubMed  Google Scholar 

  19. Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond). 2011;25:1617–21.

    Article  CAS  PubMed Central  Google Scholar 

  20. Terao R, Yuda K, Kure K, Inoue T, Ohtsu H, Yanagi Y. Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion. Jpn J Ophthalmol. 2014;58:139–45.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

Y. Nomura, None; H. Takahashi, None; X. Tan, None; S. Fujimura, None; R. Obata, None; Y. Yanagi, None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yoko Nomura.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nomura, Y., Takahashi, H., Tan, X. et al. Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration. Jpn J Ophthalmol 58, 443–447 (2014). https://doi.org/10.1007/s10384-014-0333-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-014-0333-5

Keywords

Navigation